Reply to corresponcence: "Oral immunotherapy in alpha‐gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?".

This document is a reply to correspondence regarding a study on oral immunotherapy in alpha-gal red meat allergy. The authors address potential confounding factors for galactose-alpha-1,3-galactose-specific immunoglobulin E positivity (alpha-gal-sIgE), such as asthma, pet ownership, parasites, and medication use. They discuss conflicting findings on the relationship between these factors and alpha-gal sensitivity. The authors also respond to concerns about the impact of biologic therapy on oral immunotherapy and explain the rationale behind the different protocols used in their study. They conclude that further research is needed to understand the risk factors, the impact of therapy, and the mechanisms of oral immunotherapy in alpha-gal allergy. [Extracted from the article]